Related Experiment Video

Updated: Aug 19, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Hepatic tumor growth: target for angiogenesis inhibition?

Shiva Sarraf-Yazdi1, Jing Mi, Bryan M Clary

  • 1Department of Surgery, Duke University Medical Center, DUMC, 3247, Durham, N.C. 27710, USA.

World Journal of Surgery
|February 12, 2005
PubMed

Insights

Bevacizumab, an antibody targeting tumor angiogenesis, improved survival in metastatic colorectal cancer patients. Further research into tumor microenvironment interactions is needed for better hepatic malignancy treatments.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunotherapy

Background:

  • Tumor-induced angiogenesis is critical for cancer survival and progression.
  • Targeting angiogenesis has shown promise in clinical trials for tumor inhibition.
  • Hepatic metastases are a primary cause of mortality in colorectal cancer patients.

Purpose of the Study:

  • To evaluate the efficacy of Bevacizumab in combination with chemotherapy for metastatic colorectal cancer.
  • To explore novel therapeutic strategies targeting tumor-microenvironment interactions in angiogenesis.

Main Methods:

  • Phase III clinical trial involving patients with metastatic colorectal cancer.
  • Administration of Bevacizumab (recombinant humanized monoclonal antibody against vascular endothelial growth factor) with standard chemotherapy.
  • Comparison of outcomes between Bevacizumab plus chemotherapy and chemotherapy alone.

Main Results:

  • Bevacizumab in conjunction with chemotherapy significantly increased survival, progression-free survival, response rate, and duration of response compared to chemotherapy alone.
  • The observed increase in response duration with Bevacizumab was less than 6 months.
  • Hepatic metastases remain a critical challenge in colorectal cancer patient outcomes.

Conclusions:

  • Bevacizumab demonstrates efficacy in improving outcomes for metastatic colorectal cancer.
  • There is a need for novel therapeutic approaches to overcome limitations in response duration and target hepatic malignancies.
  • Understanding complex tumor-microenvironment interactions in angiogenesis is crucial for advancing cancer therapy.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...